Dear Mr. Ayers:

Please refer to your new drug application (NDA) dated May 29, 2002, received May 29, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Alinia® (nitazoxanide) Tablets, 500 mg, NDA 21-497. Please note that this application was split and assigned a second NDA number, NDA 21-818, for our administrative purposes in the July 21, 2004 action letter. Your submission of December 17, 2004 constituted a complete response to our July 21, 2004 action letter to NDA 21-818.

Please also refer to your supplemental new drug application (sNDA) dated December 17, 2004, received December 20, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Alinia® (nitazoxanide) for Oral Suspension, 100 mg/5 ml, NDA 21-498/S-003.

We acknowledge receipt of your January 21, April 14, May 25, June 8 and June 14, 2005 submissions to NDA 21-818.

We also acknowledge receipt of your January 21, 2005 submission to NDA 21-498/S-003.

This new drug application, NDA 21-818, provides for the use Alinia® (nitazoxanide) Tablets for the treatment of diarrhea caused by Cryptosporidium parvum in non-HIV infected patients 12 years of age and older.

This supplemental new drug application, NDA 21-498/S-003, provides for the use of Alinia® (nitazoxanide) for Oral Suspension for the treatment of diarrhea caused by Cryptosporidium parvum in non-HIV infected patients 12 years of age and older.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted June 14, 2005).
The electronic labeling rule published December 11, 2003, (68 FR 69009) requires submission of labeling content in electronic format effective June 8, 2004. For additional information, consult the following guidances for industry regarding electronic submissions: Providing Regulatory Submissions in Electronic Format – NDAs (January 1999) and Providing Regulatory Submissions in Electronic Format – Content of Labeling (February 2004). The guidances specify that labeling is to be submitted in PDF format. To assist in our review, we request that labeling also be submitted in MS Word format. If formatted copies of all labeling pieces (i.e., package insert, patient package insert, container labels, and carton labels) are submitted electronically, labeling does not need to be submitted in paper. For administrative purposes, this submission should be designated “FPL for approved NDA 21-818 and NDA 21-498/S-003.” Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred.

Based on information submitted, we conclude the following:

For the treatment of diarrhea caused by Cryptosporidium parvum,

- We are deferring submission of pediatric studies for patients zero months to twelve months of age until July 22, 2009.
- You have fulfilled the pediatric study requirement at this time for patients one through sixteen years of age.

Your deferred pediatric study required under section 2 of the Pediatric Research Equity Act (PREA) is considered a required postmarketing study commitment. The status of this postmarketing study shall be reported annually according to 21 CFR 314.81. This commitment is listed below.

1. Deferred pediatric study under PREA for the treatment of diarrhea caused by Cryptosporidium parvum in pediatric patients zero months to twelve months of age.

   Final Report Submission: July 22, 2009

Submit final study report to this NDA. For administrative purposes, all submissions related to this pediatric postmarketing study commitment must be clearly designated “Required Pediatric Study Commitment”.

In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD  20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 21-497 for this drug product, not to NDA 21-818. In the future, do not make submissions to NDA 21-818 except for the final printed labeling requested above.

If you have any questions, please call Kristen Miller, Pharm.D., Regulatory Project Manager, at (301) 827-2127.

Sincerely,

(See appended electronic signature page)

Renata Albrecht, M.D.
Director
Division of Special Pathogen and Immunologic Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Renata Albrecht
6/16/05 10:54:25 AM